633 related articles for article (PubMed ID: 31825687)
1. Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present).
Takada I; Makishima M
Expert Opin Ther Pat; 2020 Jan; 30(1):1-13. PubMed ID: 31825687
[No Abstract] [Full Text] [Related]
2. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.
Evans JL; Lin JJ; Goldfine ID
Curr Diabetes Rev; 2005 Aug; 1(3):299-307. PubMed ID: 18220606
[TBL] [Abstract][Full Text] [Related]
3. PPAR dual agonists: are they opening Pandora's Box?
Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
[TBL] [Abstract][Full Text] [Related]
4. Multitargeted bioactive ligands for PPARs discovered in the last decade.
Zhang J; Liu X; Xie XB; Cheng XC; Wang RL
Chem Biol Drug Des; 2016 Nov; 88(5):635-663. PubMed ID: 27317624
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008-present).
Lamers C; Schubert-Zsilavecz M; Merk D
Expert Opin Ther Pat; 2012 Jul; 22(7):803-41. PubMed ID: 22697317
[TBL] [Abstract][Full Text] [Related]
6. Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
Shioi R; Okazaki S; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
Bioorg Med Chem Lett; 2017 Jul; 27(14):3131-3134. PubMed ID: 28539218
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.
Aleshin S; Grabeklis S; Hanck T; Sergeeva M; Reiser G
Mol Pharmacol; 2009 Aug; 76(2):414-24. PubMed ID: 19483106
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome-proliferator-activated receptors and the control of levels of prostaglandin-endoperoxide synthase 2 by arachidonic acid in the bovine uterus.
Sheldrick EL; Derecka K; Marshall E; Chin EC; Hodges L; Wathes DC; Abayasekara DR; Flint AP
Biochem J; 2007 Aug; 406(1):175-83. PubMed ID: 17516915
[TBL] [Abstract][Full Text] [Related]
9. PPARs as therapeutic targets in cardiovascular disease.
van Bilsen M; van Nieuwenhoven FA
Expert Opin Ther Targets; 2010 Oct; 14(10):1029-45. PubMed ID: 20854178
[TBL] [Abstract][Full Text] [Related]
10. Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
Honda A; Kamata S; Akahane M; Machida Y; Uchii K; Shiiyama Y; Habu Y; Miyawaki S; Kaneko C; Oyama T; Ishii I
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563117
[TBL] [Abstract][Full Text] [Related]
11. Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?
Gani OA
Cardiovasc Diabetol; 2008 Mar; 7():6. PubMed ID: 18355413
[TBL] [Abstract][Full Text] [Related]
12. Scintillation Proximity Assay (SPA)-Based Radioligand Binding for PPARα, PPARγ, and PPARδ Receptors.
Grether U; Benz J; Hartung T; Roth D
Methods Mol Biol; 2023; 2576():145-153. PubMed ID: 36152183
[TBL] [Abstract][Full Text] [Related]
13. Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding.
Batista FA; Trivella DB; Bernardes A; Gratieri J; Oliveira PS; Figueira AC; Webb P; Polikarpov I
PLoS One; 2012; 7(5):e33643. PubMed ID: 22606221
[TBL] [Abstract][Full Text] [Related]
14. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands.
Seimandi M; Lemaire G; Pillon A; Perrin A; Carlavan I; Voegel JJ; Vignon F; Nicolas JC; Balaguer P
Anal Biochem; 2005 Sep; 344(1):8-15. PubMed ID: 16038868
[TBL] [Abstract][Full Text] [Related]
15. Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
Honda A; Kamata S; Satta C; Machida Y; Uchii K; Terasawa K; Nemoto A; Oyama T; Ishii I
Biol Pharm Bull; 2021; 44(9):1210-1219. PubMed ID: 34471049
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
17. PPAR Ligands Containing Stilbene Scaffold.
Fantacuzzi M; De Filippis B; Amoroso R; Giampietro L
Mini Rev Med Chem; 2019; 19(19):1599-1610. PubMed ID: 31161987
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptors increase human sebum production.
Trivedi NR; Cong Z; Nelson AM; Albert AJ; Rosamilia LL; Sivarajah S; Gilliland KL; Liu W; Mauger DT; Gabbay RA; Thiboutot DM
J Invest Dermatol; 2006 Sep; 126(9):2002-9. PubMed ID: 16675962
[TBL] [Abstract][Full Text] [Related]
19. A pan-PPAR ligand induces hepatic fatty acid oxidation in PPARalpha-/- mice possibly through PGC-1 mediated PPARdelta coactivation.
Røst TH; Haugan Moi LL; Berge K; Staels B; Mellgren G; Berge RK
Biochim Biophys Acta; 2009 Nov; 1791(11):1076-83. PubMed ID: 19577662
[TBL] [Abstract][Full Text] [Related]
20. Cow's milk increases the activities of human nuclear receptors peroxisome proliferator-activated receptors alpha and delta and retinoid X receptor alpha involved in the regulation of energy homeostasis, obesity, and inflammation.
Suhara W; Koide H; Okuzawa T; Hayashi D; Hashimoto T; Kojo H
J Dairy Sci; 2009 Sep; 92(9):4180-7. PubMed ID: 19700678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
